Abstracts tagged "Response Criteria"

Abstract Number: 0507 • ACR Convergence 2023
The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis
Antoni Chan and NiSoe Nwe, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom
Background/Purpose: Patient-reported outcome measures (PROMs) are important tools for evaluating disease activity, functional status, and quality of life in patients with psoriatic arthritis (PsA). The…
Abstract Number: 0474 • ACR Convergence 2022
Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Javier Loricera², Monica Calderón-Goercke¹, Clara Moriano³, Santos Castañeda⁴, FRANCISCO JAVIER NARVAEZ⁵, Vicente Aldasoro⁶, Olga Maiz⁷, Rafael Melero⁸, Juan Ignacio Villa⁹, Paloma Vela-Casampere¹⁰, Susana Romero Yuste¹¹, José Luis Callejas¹², Eugenio De Miguel¹³, Eva Galíndez-Agirregoikoa¹⁴, Francisca Sivera¹⁵, Jesús Carlos Fernández-López¹⁶, Carles Galisteo¹⁷, Ivan Ferraz Amaro¹⁸, JULIO SANCHEZ MARTIN¹, Lara Sánchez-Bilbao¹, Jose Luis Hernández¹, Miguel Angel Gonzalez Gay¹⁹ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵Hospital de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donostia, San Sebastián, Spain, ⁸Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital Sierrallana, Torrelavega, Spain, ¹⁰Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital San Cecilio, Granada, Andalucia, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁶Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹⁷Hospital Parc Tauli,, Sabadel, Spain, ¹⁸Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁹Hospital Universitario Marques de Valdecilla, Lugo, Spain
Background/Purpose: Tocilizumab (TCZ) has shown to be useful in the treatment of large-vessel vasculitis, including giant cell arteritis (GCA). There is general agreement on the…
Abstract Number: 0851 • ACR Convergence 2022
Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis
Alysha Taxter¹, Laura Schanberg², Marc Natter³ and for the CARRA Registry investigators⁴, ¹Nationwide Children's Hospital, Columbus, OH, ²Duke University Medical Center, Durham, NC, ³Boston Children's Hospital, Boston, MA, ⁴CARRA, Washington, DC
Background/Purpose: The ACR Pediatric Criteria (ACR Pedi) contains a core set of outcome variables, including a measure of functional ability, to evaluate improvement over time…
Abstract Number: 0923 • ACR Convergence 2022
Identification of Cell-Specific DNA Methylation Changes Associated with MTX Treatment Response in Rheumatoid Arthritis
Cameron Adams¹, Nisha Nair², Hong Quach¹, Diana Quach¹, Joanne Nititham³, Mary Nakamura⁴, Jonathan Graf⁵, Lindsey Criswell⁶ and Lisa Barcellos⁷, ¹University of California, Berkeley, Berkeley, CA, ²The University of Manchester, Manchester, United Kingdom, ³National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁴UCSF/SFVAHCS, San Francisco, CA, ⁵Ucsf, San Francisco, CA, ⁶National Human Genome Research Institute, NIH, Bethesda, MD, ⁷School of Public Health, UC Berkeley; National Human Genome Research Institute, National Institutes of Health, Berkeley, CA
Background/Purpose: MTX is the recommended first treatment for rheumatoid arthritis (RA); however, only ~40% respond adequately to MTX. Significant joint damage can occur in the…
Abstract Number: 1019 • ACR Convergence 2022
Association Between Stringent Clinical Measures of Disease Activity and Clinically Meaningful Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: Results from KEEPsAKE 1 and 2 Clinical Trials
Alexis Ogdie¹, Joseph Merola², Roberto Ranza³, Ahmed Soliman⁴, Manish Mittal⁴, Byron Padilla⁵, Sandra Ciecinski⁶, Priscila Nakasato⁷ and Laure Gossec⁸, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Waukegan, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie Inc, Toronto, ON, Canada, ⁸Sorbonne Université, Paris, France
Background/Purpose: Assessment of disease activity in PsA patients is important to evaluate therapeutic response in clinical trials. Patient-reported outcomes (PROs) are evaluated to assess benefits…
Abstract Number: 1079 • ACR Convergence 2022
Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Vanesa Calvo Río², Javier Loricera³, Nuria Aviles⁴, Juan M Blanco Madrigal⁵, Santos Castañeda⁶, Miguel Angel Gonzalez Gay⁷ and Ricardo Blanco³, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Valdecilla Hospital, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Perpetuo Socorro, Albacete, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁷Hospital Universitario Marques de Valdecilla, Lugo, Spain
Background/Purpose: Anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is…
Abstract Number: 1147 • ACR Convergence 2022
Transcriptomic Changes Induced by Tocilizumab in Ex-Vivo PBMCs from Patients with GCA in Remission. Predictors of Response
Marco A Alba¹, Roser Alba¹, Georgina Espigol Frigolé², Javier Marco Hernández², Sergio Prieto², Marc Corbera-Bellalta³ and Maria C Cid³, ¹IDIBAPS, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Clinic, University of Barcelona, Barcelona, Spain
Background/Purpose: Glucocorticoids (GCs) are only effective therapy able to induce disease remission, but most patients relapse when GC are tapered and suffer from GC-related toxicity.…
Abstract Number: 1362 • ACR Convergence 2022
Validation of the 2016 ACR/EULAR Myositis Response Criteria in Juvenile Dermatomyositis (JDM) Clinical Trials and Consensus Profiles
Hanna Kim¹, Didem Saygin², Christian Douglas³, john mcgrath³, Jesse Wilkerson³, angela Pistorio⁴, Ann Reed⁵, Chester Oddis⁶, Frederick Miller⁷, Jiří Vencovský⁸, Nicola Ruperto⁹, Rohit Aggarwal¹⁰ and Lisa G Rider⁷, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ²University of Chicago, Chicago, IL, ³Social and Scientific Systems, Inc., Durham, NC, ⁴IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁵Duke University School of Medicine, Durham, NC, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹⁰Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Juvenile dermatomyositis (JDM) ACR-EULAR myositis response criteria (MRC) were developed based on absolute % changes in 6 core set measures (CSM) differentially weighted to…
Abstract Number: 1370 • ACR Convergence 2022
Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
Gulnara Mamyrova¹, William Nguyen², Hassan Awal¹, Derek Jones¹, Alison Ehrlich³, Kathleen Brindle⁴, Shahriar Haji-Momenian⁴, Robert Sheets⁵, Adeline Y. Chin⁶, Shajia Lu⁷, Massimo Gadina⁷, Hanna Kim⁸, Olcay Y. Jones⁹, Lisa G Rider¹⁰ and Rodolfo V Curiel¹, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Division of Rheumatology, Department of Medicine, George Washington University, School of Medicine and Health Sciences, Washington, DC, ³Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁴Department of Radiology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of California San Diego, Rady Children's Hospital, San Diego, CA, ⁶Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁷Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁸Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Pediatric Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁰Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: This open-label 24-week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (JDM).Methods: Ten patients of…
Abstract Number: 1414 • ACR Convergence 2022
2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis
Paul Studenic¹, Daniel Aletaha², Maarten de Wit³, Tanja Stamm⁴, Farideh Alasti⁵, Diane Lacaille⁶, Josef Smolen¹ and David Felson⁷, ¹Medical University of Vienna, Vienna, Austria, ²Medical University Vienna, Wien, Austria, ³Patient research partner, Amsterdam, Netherlands, ⁴Medical University of Vienna, CeMSIIS - Center for Medical Statistics, Informatics, and Intelligent Systems, Section for Outcomes Research, Wien, Austria, ⁵Medical University of Vienna, Department of Internal Medicine 3, Division of Rheumatology, Vienna, Austria, ⁶Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁷Boston University, Boston, MA
Background/Purpose: More than 10 years ago ACR and EULAR endorsed provisional criteria to define remission in RA, both Boolean and index-based. However, the agreement between…
Abstract Number: 1628 • ACR Convergence 2022
The Sjogren Tool for Assessing Response (STAR): Assessment of Response Rates Overall, According to Baseline Activity and by Domain: Reanalysis of 9 Clinical Trials in Primary Sjogren Syndrome
Raphaèle Seror¹, Gabriel Baron², Divi CORNEC³, Elodie Perrodeau², Marine Camus⁴, Professor Simon Bowman⁵, Michele Bombardieri⁶, Hendrika Bootsma⁷, Suzanne Arends⁷, jacques-eric gottenberg⁸, Benjamin A. Fisher⁹, Wolfgang Hueber¹⁰, Joel Van Roon¹¹, Valerie Devauchelle¹², Liseth de Wolff¹³, Peter Gergely¹⁴, Xavier Mariette¹⁵ and Raphaël Porcher¹⁶, ¹University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ²AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, ³CHRU Brest, Brest, France, ⁴Department of Rheumatology, Université Paris-Saclay, APHP Hôpital Bicêtre, Le Kremlin Bicêtre, France, ⁵University Hospitals Birmingham, Birmingham, United Kingdom, ⁶Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸Strasbourg University Hospital, Strasbourg, France, ⁹University of Birmingham, Birmingham, United Kingdom, ¹⁰Novartis Pharmaceuticals, Basel, Switzerland, ¹¹Rheumatology & Clinical Immunology, University of Utrecht, Utrecht, Netherlands, ¹²Université de Bretagne Occidentale, Brest, France, ¹³UMCG, Zwolle, Netherlands, ¹⁴Novartis Pharma, Basel, Switzerland, ¹⁵Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁶Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: The ESSDAI and ESSPRI, used alone, are not able to capture all features of primary Sjögren's syndrome (pSS). The NECESSITY consortium developed the Sjögren's…
Abstract Number: 1974 • ACR Convergence 2022
Which ACR Response Definition Should Be Used for Disease Activity Claims in Approval Studies of Rheumatoid Arthritis? A Systematic Evaluation
Andreas Kerschbaumer¹, Victoria Konzett², Josef Smolen¹ and Daniel Aletaha³, ¹Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology / Department of Medicine III / Medical University of Vienna, Vienna, Austria, ³Medical University Vienna, Wien, Austria
Background/Purpose: The American College of Rheumatology (ACR) response definition was developed in 1995 by Felson et al. as a composite outcome and has been the…
Abstract Number: 0293 • ACR Convergence 2022
Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND
Ronald van Vollenhoven¹, Stephen Hall², Alvin Wells³, Sebastian Meerwein⁴, Yanna Song⁵, Jessica Suboticki⁶ and Roy Fleischmann⁷, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Emeritus Research and Monash University, Melbourne, Australia, ³Aurora Rheumatology and Immunotherapy Center, Franklin, WI, ⁴AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment goal for patients with rheumatoid arthritis (RA) is sustained remission (REM), but low disease activity (LDA) is considered an appropriate target…
Abstract Number: 2014 • ACR Convergence 2022
Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up
Einer Sanchez-Prado, ronald Perez, Laura Cuellar, jonatan mareco, Santiago Ruta, Sebastian Magri and Rodrigo Garcia Salinas, Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who…
Abstract Number: 0294 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
Roy Fleischmann¹, Sebastian Meerwein², Christina Charles-Schoeman³, BERNARD COMBE⁴, Stephen Hall⁵, Nasser Khan⁶, Kyle Carter⁷, Heidi Camp⁸ and Andrea Rubbert-Roth⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ³Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ⁴Montpellier University, Montpellier, France, ⁵Emeritus Research and Monash University, Melbourne, Australia, ⁶AbbVie, Inc., Abbott Park, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Abbvie, Winnetka, IL, ⁹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: To evaluate the long-term efficacy and safety of upadacitinib (UPA) over 5 yrs among patients with rheumatoid arthritis (RA) in a long-term extension (LTE)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].